BioPharm America™ 2013 program leads with plenary on drug development pipeline “The Chameleon Rubik’s Cube”
EBD Group’s BioPharm America™ will kick off its 2013 program with an Opening Plenary entitled “Strategic R&D Planning: The Chameleon Rubik’s Cube” on Tuesday, September 17. The plenary features moderator Vaughn Kailian, Managing Director of MPM Capital and includes speakers James Hoyes, President of EMD Serono; David Meeker, CEO of Genzyme; and Roger Pomerantz, Senior VP and Head, Worldwide Licensing and Acquisitions at Merck. The panel will discuss long-term pipeline planning in drug development which can be likened to a Rubik’s cube that changes colors with its surroundings.
Other highlights of the 2013 program include a new spin on a conference favorite, Doug MacDougall’s “The Perfect Pitch: Do you have what it takes to win over investors?” and the workshop “Why can’t big pharma invest in my company?” moderated by David Collier, CEO of Velocity Pharmaceutical Development.
“This year we have changed the program to include a full afternoon of roundtable discussions to engage conference attendees as well as the executive panelists,” said Carola Schropp, President of EBD Group. “The new roundtable format will promote discussion and interaction among discussion leaders and audience members, and therefore provide yet another networking opportunity for participants.”
Parallel roundtable discussions fall into four tracks:
- The future of dealmaking;
- External and internal drivers;
- Therapeutic spotlight; and
- Welcome to the digital age.
Sixteen roundtables are scheduled. An example is “Partnering: Thinking beyond the deal,” featuring Stephane Bancel, President and Founding CEO at Moderna Therapeutics;Christoph Pittius, VP, Strategic Partnering and Business Development, Cardiovascular/Metabolic at AstraZeneca; Jason Rhodes, Executive VP and CFO at Epizyme, Inc.; Ed Saltzman, President at Defined Health; and Andrew J. Schwab, Managing Partner at 5AM Ventures discussing the drivers for dealmaking with the audience.
EBD Group, the leading partnering firm for the life science industry, produces BioPharm America in collaboration with the Massachusetts Biotechnology Council (MassBio). It will be held in Boston September 17–19 at the Westin Boston Waterfront. The bio-pharma partnering event will welcome executives from big pharma, including AstraZeneca, Bayer HealthCare, EMD Serono, Janssen, Merck, Novo Nordisk, and Shire seeking to identify and enter into strategic relationships at the global level.
BioPharm America 2012 welcomed over 750 delegates representing 462 companies from 30 countries. Delegates in 2012 engaged in 1,846 one-to-one partnering meetings with 652 licensing opportunities.
One-to-one networking at BioPharm America™ is powered by partneringONE®, the leading conference networking solution for the life sciences.
Register before July 19, 2013 to save USD 200 at www.ebdgroup.com/bpa/registration. MassBio members receive an additional USD 200 discount by adding the code ‘MassBio‘ in the comments field of the online registration form.
Presenting companies should submit an application by June 28, 2013 atwww.ebdgroup.com/bpa/presenters
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
About BioPharm America 2014
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2014 on Twitter: twitter.com/ebdgroup (hashtag: #BPA14)
Or join the Life Science Partnering group on partnering360® to kick off your partnering activities before BioPharm America, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round. Join the vibrant community of life science companies on partnerning360 today.